FibroGen, Inc. (NASDAQ:FGEN), announced on 5/21/18 that updated results from the company’s randomized, double-blind, placebo-controlled Phase 2b PRAISE study of pamrevlumab in patients with... read more
FibroGen, Inc. (NASDAQ:FGEN), announced on 5/21/18 that updated results from the company’s randomized, double-blind, placebo-controlled Phase 2b PRAISE study of pamrevlumab in patients with... read more
GRAIL, Inc., announced on 5/21/18 that it has raised USD$300 million in an oversubscribed Series C financing. The financing is led by Ally Bridge Group, co-led by Hillhouse Capital Group and 6... read more
Cosmo Pharmaceuticals N.V. (SIX: COPN) announced on 5/21/18 that the U.S. Food and Drug Administration (FDA) has set a PDUFA date of November 16, 2018 for its decision on the New Drug Application... read more
ViiV Healthcare, announced on 5/21/18 that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human... read more